Vaccine thermostability is key to successful global immunization programs as it may have a significant impact on the continuous cold-chain maintenance logistics, as well as affect vaccine potency. Modern biological and biophysical techniques were combined to in-depth characterize the thermostability of a formulated rabies virus (RABV) in terms of antigenic and genomic titer, virus particle count and aggregation state. Tunable resistive pulse sensing (TRPS) and nanoparticle tracking analysis (NTA) were used to count virus particles while simultaneously determining their size distribution. RABV antigenicity was assessed by NTA using a monoclonal antibody that recognize a rabies glycoprotein (G protein) conformational epitope, enabling to specifically count antigenic rabies viruses. Agreement between antigenicity results from NTA and conventional method, as ELISA, was demonstrated. Additionally, NTA and ELISA showed mirrored loss of RABV antigenicity during forced degradation studies performed between 5°C and 45°C temperature exposure for one month. Concomitant with decreased antigenicity, emergence of RABV particle populations larger than those expected for rabies family viruses was observed, suggesting RABV aggregation induced by thermal stress. Finally, using a kinetic-based modeling approach to explore forced degradation antigenicity data (NTA, ELISA), a two-step model accurately describing antigenicity loss was identified. This model predicted a RABV shelf-life of more than 3 years at 5°C; significant loss of antigenicity was predicted for samples maintained several months at ambient temperature. This thorough characterization of RABV forced degradation study originally provided a time-temperature mapping of RABV stability.
Introduction
The thermal stability of biologics and vaccines is of concern for the pharmaceutical industry, health authorities, government institutions, and philanthropic organizations attempting to increase the distribution of vaccines to countries with poor infrastructure, unreliable transportation and storage facilities needed to maintain a continuous coldchain.
The World Health Organization (WHO) has set guidelines on the evaluation of vaccine stability and recommends to conduct basic and accelerated stability studies [1] . Such studies are often used to determine optimal stabilizing conditions, establish shelf-life specifications, help profile changes in the stability characteristics at temperature higher or lower than recommended for storage (temperature excursions) [2] [3] [4] [5] [6] . Accelerated stability studies are currently designed to determine the rate of biological and vaccine degradation over time as a result of product exposure to temperatures greater than those recommended for storage and data are basically analyzed with Arrhenius plots. Kinetic description of the experimental data of biologicals and vaccines was obtained with the parameters derived from two-step models, mimicking the complicated degradation of the investigated samples [7, 8] . During kinetic analysis of forced degradation data, the Šesták-Berggren approach [9] is a very useful phenomenological kinetic model which allows kinetic analysis of complex reactions [10, 11] . It was demonstrated that the screening of large amount of models combined with an advanced statistical model selection resulted in the identification of appropriate kinetics models [11] which were able to accurately predict the long-term vaccine degradation either under isothermal or specific temperature excursions for virus-based vaccines in which the rate of degradation is characterized by the two-step kinetic models [10, 12] .
Mechanisms of protein degradation include both chemical and physical modifications, such as amino acid oxidation and deamidation, adsorption and aggregation phenomenon which need to be characterized to define product stability. A major degradation pathway of proteins is aggregation, known to have a detrimental effect on their stability [13] [14] [15] [16] . This physical instability can result in aggregates ranging in size from tens of nanometers with soluble oligomers to hundreds of microns with insoluble macroscopic and visible particles [17, 18] . Aggregation and particulate matter have to be documented in products with parenteral administration such as vaccines. Considerable progress has been made in our understanding of the aggregation propensity of biologics, including vaccines [19] [20] [21] and their link with immunogenicity, for biotherapeutics but also for vaccines [22] [23] [24] [25] [26] [27] . As such, guidelines and criteria for particles above 10 µm and 25 µm in therapeutic formulations are available in Pharmacopeias [28] [29] [30] [31] . More recently, recommendations for counting particles comprised in the size range of 2-10 µm [32] were provided for therapeutic protein products and a guidance for characterization of particles of smaller size ranges (0.1-2 µm) was drafted [33] .
There are a number of analytical complementary techniques available for the assessment of subvisible particles in biologics [34, 35] . As significant parts of proteinaceous aggregates and particles are not captured by conventional methods described in USP 〈7 8 8〉, namely microscopy and light obscuration technics, it is essential to use alternative and additional methods [36] . Among these, tunable resistive pulse Sensing (TRPS) and nanoparticle tracking analysis (NTA) are suitable for the determination of particles ranging from few tens to several hundreds of nanometers, in agreement with many viruses. Based on orthogonal principles, these techniques allow for the simultaneous determination of particle size distribution and concentration [37] [38] [39] [40] [41] [42] [43] . It was shown that TRPS appropriately measures concentrations of biological nanoparticle dispersions [37] , such as viruses [38, 39] . NTA is appropriate for counting viruses as small as Encephalomyocarditis virus or Brome mosaic virus [42] , with a diameter around 35 nm and for detection of particles up to 1000 nm, determining aggregation state in complex formulations such as seasonal influenza vaccines [43] or poxvirus-based (vaccinia virus) solutions [44] .
The study presents the characterization of RABV degradation during thermal stress by using different cutting-edge orthogonal methods (e.g. viral-specific particle counting and sizing) in order to provide a complete time-temperature mapping of RABV stability thanks to a kineticbased modeling approach. For this purpose, well-known rabies vaccine, especially a Purified Vaccine New Generation (PVRV-NG) bulk, known as RABV, was used as a model.
Material and methods

Cells and viruses
The Wistar Rabies Pitman Moore/WI 38 1503-3M strain, originally isolated by Louis Pasteur [59] was used for antirabic vaccine production at industrial scale, produced on Vero cell line in a serum-free manner and inactivated by β-propiolactone. This Purified Vero cell Rabies Vaccine New Generation (PVRV-NG) bulk, here renamed as RABV, was used as a colloidal particle model in this study. RABV was formulated in stabilizer containing a mixture of excipients (amino acids, sugar, surfactant and chelator) in a phosphate buffer to maintain pH at 8. Samples initially stored at −70°C were thawed overnight under refrigerated conditions before use.
Stability monitoring by thermal stress
RABV samples were incubated in a cold chamber at 5°C and in incubators at 25°C, 37°C , 40°C, 45°C and 60°C for up to 7 months. The cold chamber was maintained ± 3°C and incubators at ± 1°C. An unstressed control was stored at −70°C. During this forced degradation study, RABV was sampled after various times and analyzed by NTA, ELISA, ddPCR, DSF and DLS. 2 months data were used for ELISA stability modeling and experimental values obtained after 7 months at 5°C and 25°C were compared to predicted antigenicity.
Enzyme-linked immunosorbent assay (ELISA)
An ELISA described to specifically quantify antigenicity of folded protein G covering the surface of rabies was applied, in which D1-25 mAb is used in the detection step (for a detailed protocol and method precision, see [60] ). This ELISA was recently identified as a potential assay of choice by the European Directorate for the Quality of Medicines and Healthcare (EDQM) collaborative study aimed at replacing the rabies vaccine National Institute of Health (NIH) in vivo potency test [60] .
Nanoparticle tracking analysis (NTA)
Data was collected using a NS300 (laser 488 nm) from Malvern Ltd (Worcestershire, UK), according to the ASTM standard guide [61] . Serial dilutions of RABV, from 1/100 to 1/20,000, were prepared in PBS (CXXPBS00-01 Eurobio, Les Ulis, France) to assess NTA linearity range in comparison with ELISA and ddPCR; these characterizations were done from the same sample dilution. A minimum of 1000 Validated Tracks was obtained for 3 independent videos of 60 sec. acquisition or 120 sec. for the lowest dilutions of the standard. Agreement between NTA and conventional ELISA method was preliminary studied between 10 7.5 and 10 9.5 particles/mL concentrations. On the whole linearity range, coefficient of variation of NTA method was of 5% in particle sizing (mean diameter), demonstrating that no significant impact of particle concentration was observed on size determination. Stressed RABV samples were diluted prior to analysis, 1:500 in PBS so as to be in the NS300 linear range. Live monitoring NTA acquisition was performed using a syringe loading system. In order to improve sample representativeness a minimum of 1000 Total Valid Tracks were required to validate each experimental serie and the acquisition time was adjusted to obtain this significant Valid Track number. RABV samples were incubated for 1 h at 37°C with anti-G D1-25 mAb, directly conjugated to Alexa Fluor® 488 by BIOTEM (Apprieu, France), at 1:200 dilution in PBS. NTA data acquisition was done using a 500 nm long pass filter to count fluorescent virus particles with bound D1-25 mAb (named as anti-G NTA) and without filter to obtain total particle count on the same dilution sample. Focus was optimized to count small and large particles. Detection threshold (5 for total particle acquisitions and 7 for labelled particle acquisitions), limiting background noise, and Camera Level (12 for total particle acquisitions and 16 for labelled particle acquisitions) settings were maintained unchanged between sample acquisitions. Three independent sample preparations were each analyzed 3 times for 60 s at 25°C. Track length was set according to Patois et al [43] recommendations (> 5). Data were processed with NanoSight NTA 3.1 Software (Malvern Ltd, Worcestershire, UK). The percentile diameter ratio (D90-D10)/D50, named as Span, was used to express polydispersity of the particle size distribution.
Tunable resistive pulse sensing (TRPS)
TRPS measurements were performed using qNANO (Izon Science Ltd., Oxford, UK). RABV samples were analyzed after 1:10 dilution in PBS 2X, according to the manufacturer recommendation. Particles records per analyse were set at a minimum of 1000 particles. Size-tunable nanopores of a polyurethane membrane NP200 were used (5 mm of stretch, 0.9 V voltage). Samples were run in triplicate. Calibration was performed using carboxylated polystyrene calibrated particles CPC200 (Izon Science Ltd., Oxford, UK) as standards, according to the manufacturer's instructions. Number-based particle size distributions were acquired with Izon V3.0 Control Suite Software (Izon Science Ltd., Oxford, UK) and mode and total concentrations calculations were derived from the individual particle measurements.
Dynamic light scattering (DLS)
Particle size was evaluated by DLS using the NanoZS instrument (Malvern Ltd, Worcestershire, UK). Samples of 100 µL were allowed to equilibrate at 25°C for 2 min. to ensure temperature homogeneity prior to making three measurements, each consisting of 10 individual runs. The viscosity and refractive index values used were those of water, as provided in the Zetasizer software (version 5.5, Malvern Ltd, Worcestershire, UK). The data was analyzed using the General Purpose Model algorithm.
Droplet digital polymerase chain reaction (ddPCR)
RNA was extracted from RABV samples using QIAamp Viral RNA kit (QIAGEN, Ltd, Hilden, Germany). A 5 µL volume of each RNA extract was mixed with 20 µL of One-Step RT-ddPCR Kit for Probes (Bio-Rad, Hercules, CA, USA) Mix and then submitted to the drop generator QX200™ Droplet Digital™ PCR System (Bio-Rad, Hercules, CA, USA) according to the manufacturer instructions. Each drop may contain a unique RNA fragment. Viral RNAs were amplified using two primers specific for the N gene between nucleotidic position 617-723. Amplicon contents were analyzed with QX200 Quanta Software (Bio-Rad, Hercules, CA, USA) and expressed as a concentration of equivalent genome. This ddPCR genomic titer could be used to estimate the physical viral particle number since nucleic acids are demonstrated to be at the level of traces in these RABV samples (< 100 pg DNA in filled product) resulting from successive steps of the actual manufacturing process.
Differential scanning fluorimetry (DSF)
SYTO 9 Green Fluorescent Nucleic Acid Stain (Invitrogen, Carlsbad, CA, USA) was used to detect when the RABV nucleic acid is released or exposed. The maximum fluorescence intensity and the temperature at which the genomic material release (T R ) were determined as previously described [62] . Volumes of 18 µL of RABV samples were dispensed into Hard-Shell multi-well plates (Bio-Rad, Hercules, CA, USA) and 2 µL of SYTO 9 stock solution at 50 µM in DMSO added. The plates were then sealed with a Microseal® 'B' Adhesive Seals (Bio-Rad, Hercules, CA, USA) and centrifuged for 2 min at 1000 rpm before measurement with a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Excitation and emission wavelengths were 483 nm and 500 nm, respectively. Samples were submitted to a temperature ramping of 1.6°C/min. from 20°C to 90°C. Derivative signals of SYTO 9 fluorescence were analyzed by the CFX Manager v2.1 software (BioRad, Hercules, CA, USA).
Kinetic-based modeling and stability predictions
AKTS-Thermokinetics software (version 4.3, AKTS AG, Advanced Kinetics and Technology Solutions, Siders, Switzerland) was used to screen and compare kinetic models of loss of antigenicity as a function of time and temperature and predict the loss of RABV antigenicity. ELISA antigenicity data obtained from RABV samples after 2 months of forced degradation were used to inform the modeling method. The general modeling procedure has been previously described in details [10] [11] [12] . Briefly, large variety of models based on the truncated Šesták-Berggren equation were analyzed and evaluated according to a leastsquare regression analysis. The best model was identified according to the higher AIC (Akaike information criterion) and BIC (Baysian information criterion) weighted scores [11] . Finally, 95% percentile confidence intervals were calculated using bootstrap analysis (resampled 1000 times with replacement) [11] .
The selected kinetic model was used to predict the course of RABV antigenicity loss during storage under isothermal conditions up to 3 years (long term stability) and during exposures under real atmospheric temperature profiles (average minimum and maximum daily (24 h) temperature per month [63]) at Conakry, in Guinea.
Results
RABV viral particle sizing and counting
Particle size distribution and counting of 'unstressed' RABV were first determined by NTA and TRPS. Similar profiles were obtained from both techniques, with particle size diameters ranging approximately from 100 nm to 250 nm with a mean population peak around 150 nm, in agreement with the expected size of rabies family viruses, expressed as spherical equivalent diameter (Fig. 1) . The dynamic light scattering (DLS) profile displayed a broader size distribution than NTA and TRPS; particle size diameters ranged from approximately 100 nm to 350 nm, with a mean of 184 nm (Fig. 1) . Full width at half maximum (FWHM) of RABV size profiles were significantly different at 98 ± 5 nm, 28 ± 3 nm and 16 ± 1 nm for DLS, NTA and TRPS, respectively.
The concentration of total particles was determined as 4.16 ( ± 0.10) × 10 10 particles/mL and 1.37 ( ± 0.50) × 10 10 particles/mL with NTA and TRPS, respectively. Comparable results were obtained by NTA for particle size distribution and concentration, with or without RABV-specific labelling using a conformation-specific monoclonal antibody [mAb] that recognizes the rabies glycoprotein G (anti-G NTA; Fig. 1b ). Low polydispersity of RABV was illustrated by the small proportion of particle populations above 200 nm (7% of the total counted particles), with and without anti-G labelling. These results indicated that the physical particle population mainly comprised antigenic viral particles (mean fluorescence labelling yield was of 91 ± 6%), demonstrating that NTA is able to specifically count antigenic RABV viruses. The genomic concentration determined by droplet digital polymerase chain reaction (ddPCR) of 1.50 ( ± 0.10) × 10 10 Geq/mL was in agreement with the TRPS value.
3.2. Concomitant increase of polydispersity in particle size distribution and loss of antigenicity during thermal degradation of RABV Data from forced degradation of RABV were periodically collected over one month and included biological (ELISA, ddPCR) and biophysical characterization (NTA, DLS, DSF) from RABV samples placed under refrigerated conditions (5°C) and elevated storage temperatures (25°C, 37°C, 40°C, 45°C). Negative and positive control samples were established by incubating RABV samples at −70°C and at 60°C, respectively. The positive control temperature (60°C) was chosen close to the release temperature (T R = 63°C) as determined by DSF (Fig. S1) .
Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.ejpb.2018.08.006.
Forced degradation induced significant changes in the physical properties of viral particles. An increase in the average particle hydrodynamic diameter with increased temperature as observed by DLS (Fig. 2a) was the signature of the appearance of larger particle populations. The polydispersity, expressed as a Span value measured on the total particle population by NTA, indicates that there is increased particle size distribution at incubation temperature of 37°C and higher incubation temperatures (Fig. 2b) . Additionally, the increase in particle polydispersity under thermal stress over time was accompanied by a continuous loss of G protein antigenicity; the kinetic profiles of loss of G protein antigenicity over time as measured by ELISA (Fig. 2c) and NTA (Fig. 2d) were similar and appeared as superimposed. Approximately 50% of antigenic particles were lost after 28 days at 37°C, 14 days at 40°C or 6 h at 45°C (Fig. 2d) . No antigenic particles were detected after 14 days at 45°C or after a few hours at 60°C. Viral genome quantity (Fig. 2e ) and genetic material accessibility (Fig. 2f ) of RABV stressed samples were shown to be stable for 28 days at 5°C and up to 40°C. When viral particles were heated up to 90°C following DSF protocol conditions, genetic material was shown to be accessible at approximately 63°C (T R ) (Fig. S1) . The DSF accessibility of genomic material profiles remained relatively unchanged after thermal stress up to 40°C. In contrast, the fluorescence intensity decreased as a function of incubation time when RABV was pre-exposed at 45°C and 60°C (Fig. S1) , suggesting the accessibility of genomic material at these temperatures. Consistent with these observations, the genome titer dropped after exposure for 15 days at 60°C, likely due to the degradation of the ddPCR nucleic target (Fig. 2e) .
Focusing on NTA size distribution profiles of RABV at 5°C and 25°C incubation temperatures over one month, virus population did not significantly change in size and counting ( Fig. 3a and b) . However, at 37°C incubation temperature or higher, there was a decrease in the concentration of particles with a mean size of 150 nm (the rate of decrease increased with temperature) that was accompanied by the concomitant emergence of larger particle size populations (Fig. 3c-f) . , and accessibility of genomic material by SYTO 9 fluorescence intensity by DSF (f). One representative experiment of at least 3 independent experiments of thermal stress program is represented and time-point sampling is common for the 6 readouts. For ELISA, NTA, ddPCR, each point is a mean of 3 measurements of independent sample test portions. For DLS, each data point represents a mean of 3 sample measurements. For DSF, each data point represents one measurement. Experimental coefficients of variation were of 3% for DLS, 6% for NTA polydispersity, 7% for ELISA, 6% for anti-G NTA concentration, 13% for ddPCR, 3% for DSF.
RABV antigenicity modeling and long-term stability predictions
An appropriate kinetic model was developed and implemented to predict the impact of storage temperatures on RABV antigenicity over the long-term using the G protein antigenicity data obtained with the ELISA after two months forced degradation. Multiple models, from the simplest to the more complex, were automatically screened to fit the experimental data obtained at 5°C, 25°C, 37°C, 40°C, 45°C and 60°C. The kinetic parameters (A: pre-exponential factor, E: activation energy, n: reaction order, m: a parameter introduced to take into account the possible autocatalytic behavior of reaction) were systematically adjusted during the fitting procedure, comprising 'one-step' or 'two-step' models [11] . Based on the sum of residual squares (RSS) value, the Akaike's Information Criterion and the Bayesian Information Criterion (wAIC and wBIC weighted scores, Table 1 ), a 'two-step' reaction was selected as the best kinetic model to describe RABV degradation data. The chosen two-step model was defined as follows:
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The pre-exponential factor was higher for the second step than the first (A2 ≫ A1). The activation energy was higher for the first step than the second (E1 > E2). The selected model (Eq. (1)) was used to simulate the RABV antigenic stability over 3 years at 5°C, 25°C, 37°C and 45°C, including the predictive 95% confidence interval (95% CI) band at 5°C and 25°C (Fig. 4) . Stable antigenicity (as referred to t = 0) ranging between 94% and 112% of that determined at the start was predicted for at least 3 years for samples kept at 5°C. Of note, the experimental data generated for 2 months at 5°C and 25°C fell within the 95% CI predictive band determined by bootstrap analysis (Fig. 4) . A gradual decrease in antigenicity over time was predicted at 25°C, with a mean decrease to 73% [95%CI, 58-92%] at 1 year, and to 50% [95%CI, 31-81%] after 2.2 years. Rapid loss in antigenicity were predicted at 37°C, 40°C and 45°C incubation temperatures, with near to complete loss after a few weeks. In addition, the RABV antigenicity at 7 months at 5°C and 25°C was predicted in the 95% CI range [94-112%] and [72-100%], respectively and was later confirmed experimentally respectively at 111% and 87% (Fig. 4) . Of major practical interest, the kinetic-based modeling approach can be used to predict, in real time, the level of product degradation provided that the temperature regimen suffered by samples is continuously recorded [12] . We also simulated the continuous degradation profile of RABV stored at ambient temperature in Conakry (Guinea) in comparison with a sample stored in a cold chamber. In Conakry, more than 60% of antigenicity was lost after 2 years at ambient temperature, thereby confirming that the cold chain should be carefully controlled to prevent RABV degradation due to temperature excursions (Fig. S2) . Fig. 3 . Impact of forced degradation of RABV on NTA size distribution profiles. RABV was incubated at 5°C (a), 25°C (b), 37°C (c), 40°C (d), 45°C (e), and 60°C (f). Dashed lines depict the profiles for sample kept at −70°C (control). One representative experiment is represented: the sample set was the same than in Fig. 2 . Each curve is a mean of 3 measurements of independent sample test portions.
Table 1
Comparison of kinetic models describing RABV antigenicity by ELISA, including model ranking parameters and kinetic parameters. Zero-and first-order for one-step models and best ranked two-step model are presented. 
Discussion
This study shows that decrease in G protein antigenicity is induced by thermal stress and is associated with a concomitant RABV particle aggregation. This appropriate forced degradation program comprising of 5 incubation temperatures enables to map and predict long-term virus stability.
RABV particle size distribution, as determined by two orthogonal technics, TRPS and NTA, was monomodal with low polydispersity at mean diameter size of about 150 nm. Knowing that rabies viruses have a typical "bullet" shape [45, 46] with a width of 75 nm and length ranging from 130 nm to 380 nm [47] , equivalent area particle diameters would range from 100 nm to 160 nm, comprising the mean diameter size measured at 150 nm. In another study, vesicular stomatitis virus (VSV) was also shown to be in this size range by TRPS and TEM (108 nm and 112 nm, respectively) [48] , corresponding to rhabdovirus expected size. The RABV particle size distribution as determined by DLS was also monomodal but with higher polydispersity than that determined with NTA and TRPS, and with a higher mean diameter of 184 nm (Fig. 1) . This bias towards the higher size particles with DLS is well known as the larger particles within the sample scatter light more intensely than the smaller particles.
To estimate size polydispersity of RABV, FWHM were determined at 98 ± 5, 28 ± 3 and 16 ± 1 nm, for DLS, NTA and TRPS respectively. Definitively higher than monodisperse polystyrene beads used as control, these results confirmed a mixture in size of viral particles. DLS exhibited the much poorer resolution with the higher FWHM value. Counting-based techniques (NTA and TRPS) showed much better resolutions with lower FWHM values compared to DLS. Several studies previously investigated performance of such orthogonal technics for subvisible sizing characterization. Comparing nanoparticle tracking analysis (NTA), tunable resistive pulse sensor (TRPS) and dynamic light scattering (DLS), transmission electron microscopy (TEM) and differential centrifugal sedimentation (DCS), it was observed that only TRPS and DCS techniques were sufficient to resolve three standard polystyrene beads (220 nm, 330 nm and 410 nm) when mixed in one suspension [49] . Additionally, NTA is highly more capable than DLS at detecting individual particle populations in multimodal samples [50] . Our results were aligned with these previous findings, confirming for RABV particles that the electric-based technique (TRPS) is the most resolute method, closely followed by NTA, DLS showing low resolution and overestimated size distribution, as impacted by low proportion of particles above 150 nm. Finally, it can be stated that RABV were mainly composed by a population of approximatively 150 nm with low proportions of additional viral particles around that size. As NTA tracks particles within a known illuminated volume of liquid, sizing and counting of nanoparticles were simultaneously performed, producing direct size distribution profiles in number. This technique was already used for rapid estimation of total particle concentration at the expected size during purification processes [40] and was considered an appropriate biophysical tool for the characterization of complex samples such as vaccines [43] . In RABV samples, using a monoclonal antibody (mAb) which targets the surface G protein, we demonstrated for the first time, to the best of our knowledge, that antigenic viral particles could be simultaneously counted and sized. Antigenic viral particles constituted more than 90% of the physical particle population under these conditions (Fig. 1b) , in accordance with the RABV high level of purity. This experiment illustrated that NTA allows for possibility to determine the ratio of antigenic/total particles in solution, in the same sample. Our results demonstrated an agreement between antigenic particle concentration (NTA), antigenic titer (ELISA using the same detection mAb) and genomic titer (ddPCR). The major interest of NTA is the real-time visualization of virus Brownian motion providing specific quantification of physical virion particles, while supplying additional information such as particle size diameter, concomitantly, and visualization of viral populations. Furthermore, in agreement with previous results [51, 52] , during the course of this study NTA has proven to be an effective biophysical technique providing high repeatability.
During forced degradation studies, loss of RABV antigenicity observed by ELISA (Fig. 2c) was concomitant to at least two physical parameter changes as shown by NTA; a loss in the number of RABV particles at the expected mean size (Fig. 2d) and a more polydisperse distribution of particles (Fig. 2b) . These results demonstrated that, in our conditions, RABV particle polydispersity inversely correlates with antigenicity.
As aggregation is one of the main physical degradation pathway of proteins, such phenomenon is usually observed when biologicals, including viruses are exposed to elevated incubation temperatures [53] . Our results demonstrated that NTA can be applied on virus-based solution to simultaneously count antigenic viral particles and determine aggregation state of virus particles. As low polydispersity was experimentally associated with high antigenicity, NTA can advantageously be used during process development of vaccines as a monitoring tool. Hence, NTA biophysical technology appears to be mature enough to be used as a robust stability-indicating method for characterization of submicron particles in biologicals (i.e. sub-visible aggregates).
To estimate if loss of antigenicity observed during forced degradation can also occur during long-term RABV storage under standard conditions (5°C or ambient temperature), we kinetically modeled the loss of antigenicity as a function of time and temperature. The selected model indicated a two-stage degradation profile; rapid decrease in antigenicity at the beginning followed by a long gradual decrease stage (Fig. 4) . This two-stage degradation profile has been described during accelerated stability studies of several enveloped viruses (measles [54] , attenuated rinderpest [55] , canine distemper [56] vaccines, recombinant canarypoxvirus [10] , and freeze-dried live, attenuated viral vaccines [12, 57] ) regardless of the readout used (e.g. infectious tiers, antigenic titers) [12, 54, 57, 58] . One hypothesis for such biphasic behavior entails the presence of at least two components with different degradation kinetics that are affected by the thermal treatment [54, 58] (e.g. epitope unfolding, capsid integrity loss, major virus conformational reorganization, key protein functionality loss or any adaptive viral strategy as population). However, it is necessary to clearly underline that such behavior only depicts a phenomenological mathematical model to fit to the loss of antigenicity data observed and does not have a real mechanistic explanation. Nonetheless, such advanced kinetic approach accurately predict product antigenicity under any storage temperature (e.g. temperature excursions during shipments, maintaining vaccine products at ambient temperature anywhere in the Fig. 4 . Long-term RABV antigenicity predicted by two-step kinetic model. Antigenicity predictions for 3 years at 5°C (blue), 25°C (red), 37°C (green), 40°C (pink), and 45°C (grey). ELISA data used for kinetic modeling are displayed as filled circles. At 5°C and 25°C, antigenicity predictions (lines) are shown with predictive band representing 95% CI (dotted lines). Additional experimental data obtained after 0.6 years at 5°C and 25°C (not used for kinetic modeling), are displayed as open circles. Each point is a mean of 3 measurements of independent sample test portions.
world, …), with few percentage points error [12] .
A significant loss of antigenicity was predicted at 25°C over 3 years, whereas at 5°C the RABV antigenicity remained unchanged; long-term stability was predicted at 5°C for more than 3 years. Maintaining RABV at ambient temperature for two years, for example in Conakry (Guinea), can have a dramatic impact on the product antigenicity with a predicted loss of 35% after 6 months (Fig. S2) . Counted antigenic particle losses as a function of time and temperature were also conveniently described by fitting NTA forced degradation data, assuming a two-step type model. In our hand, NTA did not demonstrated sensitivity to any matrix interference which constitutes an asset for optimization of product formulation, in addition to its orthogonality.
Overall, our study indicates that the kinetic analysis of RABV particle polydispersity and antigenicity defines a specific time-temperature stability mapping, emphasizing the importance of orthogonal analytical strategies to build a broader understanding of virus stability.
